All News
Thinking Outside the Box: Novel Strategies for Early Detection of AxSpA
Strategies to identify patients with suspected inflammatory back pain in the general population is critical for timely and proper diagnosis.
Read Article
We'll be going live with our #ACR22 daily recap at 5pm ET. Find us on Twitter, LinkedIn, Youtube and Facebook. https://t.co/hjAyOOynZM
Dr. John Cush RheumNow ( View Tweet)
Aggarwal @docrota et al. RCT abatacept in IIM - 52 week results. IMACS DOI, FI-2, HAQ-DI, CDASI, TIS, MRC response all numerically better, some statistically significant. There looks like a real effect across all subtypes. @RheumNow #ACR22 Abstr#2237 https://t.co/NdkH8BnSEw https://t.co/l7ufagjniX
Richard Conway RichardPAConway ( View Tweet)
Kim et al. After first episode VZV in RA or UC treated with JAKi, continued JAKi use does not increase reactivation compared to cessation. @RheumNow #ACR22 Abstr#2220 https://t.co/zx96xgkySU https://t.co/KdniDGCUgI
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#1656 Promising therapy for #lupus. Cenerimod, S1P1 modulator, controls lymphocyte trafficking out of lymph nodes into blood. Phase 2 dose-ranging RCT didn't meet primary endpoint (adjusted for multiple testing) but mSLEDAI-2K reduced in 4mg dose vs PBO @RheumNow https://t.co/YnENTkqClk
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr #2194- What is my risk of flare after COVID vaccine?
- Up to 3 wks s/p vaccination, no significant assn w/ risk for flare (aIRR 0.89 95% CI 0.8-.098) including after 1st, 2nd, and 3rd dose
- No significant assn by disease, hx of COVID infxn, vaccine type
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
Some RA patients do well.
Some do badly, and get frail even before the age of 65 (6% of pts).
These are the ones that get hit by infections with b/tsDMARDs: see below from MarketScan data. These are the patients we need to watch & protect!
ABST2217 @NamrataRheum #ACR22 @RheumNow https://t.co/DXZjFDnCcn
David Liew drdavidliew ( View Tweet)
Nakafero et al. Self-controlled case series analysis. No increased risk RMD flare with SARS-CoV-2 vaccination. In fact reduced risk! aIRR 0.89(0.80-0.98). No evidence in any of multiple subanalyses either @RheumNow #ACR22 Abstr#2194 https://t.co/r5pOkdjnR1 https://t.co/YpwMkJ3WVe
Richard Conway RichardPAConway ( View Tweet)
ACRTIC REWIND finds RA pts w/ sustained clinical remission for at least two years and successfully tapered csDMARDs to half-dose, majority of pts who discontinued csDMARDs remained flare free for 12 months. Abs 2013 #ACR22 @RheumNow https://t.co/HsQz0cJznp https://t.co/QceTXJZiFF
Dr. Rachel Tate uptoTate ( View Tweet)
🌱Plants for joints 🌱
👉16wk
👉whole food plant based diet + Phys activity + stress Mx
👉 metabolic syndrome assoc OA hip/knee
💥 substantial ⬇️ pain + stiffness
💥⬆️ physical function
#ACR22 @RheumNow Abst 1644 https://t.co/u6UufpbrcC
Patricia Harkins DrTrishHarkins ( View Tweet)
Thanks for the love #Philly #ACR22 @RheumNow check out our coverage by logging on to https://t.co/xF1bNhZB1C! https://t.co/ncBM0icZ3c
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Retrospective cohort study 132 immune checkpoint inhibitor arthritis pts Rx with either TNFi ± MTX or IL6Ri ± MTX have a shorter time to cancer progression but faster arthritis control than patients Rx with MTX alone. Bass A Abs#1669 https://t.co/h0Nq6yd2wf #ACR22 @RheumNow https://t.co/XfXMtdbCPB
Dr. Antoni Chan synovialjoints ( View Tweet)
Wallace @BethIWallace et al. Time dependent evaluation GCs and MACE in RA. Effect of steroids in previous 6 months on MACE risk in next 6 months. Odds MACE (vs no steroid) 1.54 (1-7 days) 1.78 (8-90 days) 2.17 (>90 days) @RheumNow #ACR22 Abstr#2219 https://t.co/w4gCgjeSNa https://t.co/TQ9pufGtBD
Richard Conway RichardPAConway ( View Tweet)
Sphygmomanometer for fibromyalgia detection in rheum OPD
🔥⬆️local pain during BP testing strongly indicates presence of FMS
✅useful, easily applicable and practical screening tool
Abst#1225 #ACR22 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
#FMF 2350 pts = 40% with arthritis
- Colchicine resistance in 20%
- M694V mutation carrier rate high (mutant MEFV gene)
- FMF pts with arthritis have a more severe disease course
- incidence of spondyloarthropathy was increased in FMF
#ACR22 @RheumNow abst#1830 https://t.co/uiLhjK0UjY
Bella Mehta bella_mehta ( View Tweet)
Rohmer @TerrierBen et al. 196 cases of PAN from France. 28% assoc another condition - MDS and cancer mainly. Relapse in 39% - assoc age>65, GI, skin necrosis. Death assoc age>65, AKI, secondary PAN, necrotic purpura. @RheumNow #ACR22 Abstr#2232 https://t.co/fyJY9O3Gm7
Richard Conway RichardPAConway ( View Tweet)
Tonight! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan
@RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22
https://t.co/j13W4GM56w https://t.co/fgDwPVdskC
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Richard Conway RichardPAConway ( View Tweet)
Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer
- % serious infection in TNFi in high vs low placental transfer (2.1% vs 1.6%)
- HR (high vs low) 0.98 (95% CI 0.36-2.61)
- No significant difference in risk of serious infxn
@RheumNow #ACR22 https://t.co/7Lfpf7PERu
Akhil Sood MD AkhilSoodMD ( View Tweet)
